High Risk vs. “Metabolically Healthy” Phenotype in Juvenile Obesity – Neck Subcutaneous Adipose Tissue and Serum Uric Acid are Clinically Relevant

Abstract

Background:

Since obesity and its associated co-morbidities do not only have effect on the individual patient, but also on society and the health system, it is of great importance to investigate this lifestyle-disease. The rationale of this study was to distinguish metabolically healthy from unhealthy overweight/obese patients as compared to healthy normal weight children and adolescents by means of a comprehensive anthropometric, laboratory and sonomorphological vascular assessment.

Material and methods:

299 study participants were derived from the prospective, observational study STYJOBS/EDECTA (STYrian Juvenile Obesity Study/Early DEteCTion of Arteriosclerosis). Standard anthropometric data were obtained for each subject. This study comprised different diagnostic steps: extended anthropometry (Lipometer^®), carotid artery ultrasound, various laboratory measurements, blood pressure measurement, oral glucose tolerance test. Ow/ob juveniles were classified as “metabolically healthy” (no laboratory criteria of metabolic syndrome fulfilled) vs. “metabolically unhealthy” (≥ 3 criteria of metabolic syndrome). Results underwent statistical evaluation, including t-test or Mann-Whitney U-test, regression analysis and a p-value < 0.05 was considered statistically significant.

Results and Discussion:

In the study’s central European cohort only about 16% (n=48/299) of the overweight/obese juveniles can be regarded as metabolically healthy. About 36% (n=108/299) of the overweight/obese patients fulfilled the criteria for metabolic syndrome. High visceral fat stores (p<0.001) and their clinical surrogate waist circumference (p<0.001) determine an adverse metabolic phenotype. Several parameters, including uric acid (p<0.001), adiponectin (p<0.05), insulin resistance (HOMA-Index, p<0.001), nuchal SAT thickness (p<0.001), arteriosclerosis of the carotids (p<0.001), and others are responsible for the distinction between ­metabolically healthy and unhealthy juveniles. Nevertheless, “healthy obesity” only defines a sub-phenotype of a disease effecting rising numbers of young patients.

Conclusion:

Since obesity in children and adolescents is not a consistent entity, it remains crucial to differ between metabolically healthy and unhealthy obese children in order to achieve appropriate intervention and prevention for our patients.

Key words

metabolic features - obesity - cardiovascular incidences

• References

• 1 Stewart ST, Cutler DM, Rosen AB. Forecasting the Effects of Obesity and Smoking on U.S. Life Expectancy. NEJM 2009; 361: 2252-2260
• 2 Schmid A, Schneider H, Golay A et al. Economic burden of obesity and its comorbidities in Switzerland. Soz Praventivmed 2005; 50: 87-94
• 3 Ärnlöv J, Ingelsson E, Sundström J et al. Impact of Body Mass Index and the Metabolic Syndrome on the Risk of Cardiovascular Disease and Death in Middle-Aged Men. Circulation 2010; 121: 230-236
• 4 Blüher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol 2010; 21: 38-43
• 5 Tataranni P. Treatment of Obesity: Should We Target the Individual or Society?. Current Pharmaceutical Design 2003; 9: 1151-1163
• 6 Camhi SM, Katzmarzyk PT. Tracking of cardiometabolic risk factor clustering from childhood to adulthood. IJPO 2010; 5: 122-129
• 7 Cole TJ, Bellizzi MC, Flegal KM et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-1243
• 8 Möller R, Tafeit E, Smolle KH et al. “Lipometer”: determining the thickness of a subcutaneous fatty layer. Biosens Bioelectron 1994; 9: xiii-xvi
• 9 Calori G, Lattuada G, Piemonti L et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care 2011; 34: 210-215
• 10 Möller R, Horejsi R, Pilz S et al. Evaluation of risk profiles by subcutaneous adipose tissue topography in obese juveniles. Obesity (Silver Spring) 2007; 15: 1319-1324
• 11 Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality?. Diabetes Care 2009; 32: 2297-2299
• 12 Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480
• 13 Zimmet P, Alberti KG, Serrano Ríos M. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results. Rev Esp Cardiol 2005; 58: 1371-1376
• 14 Steinberger J, Daniels SR, Eckel RH et al. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009; 119: 628-647
• 15 Kiechl S, Willeit J. The natural course of atherosclerosis. Part II: vascular remodelling. Bruneck Study Group. Arterioscler Thromb Vasc Biol 1999; 19: 1491-1498
• 16 Pignoli P, Tremoli E, Poli A et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-1406
• 17 Sims EAH. Characterization of the syndromes of obesity. In Diabetes mellitus and obesity. Edited by Brodoff BN, Bleicher SJ. Baltimore, MD: Williams and Wilkins; 1982: 219-226
• 18 Bell LM, Byrne S, Thompson A et al. Increasing body mass index z-score is continuously associated with complications of overweight in children, even in the healthy weight range. J Clin Endocrinol Metab 2007; 92: 517-522
• 19 Winkelmann BR, Marz W, Boehm BO et al. Rationale and design of the LURIC study – a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001; 2: 1-73
• 20 Evans EW, Sonneville KR. BMI report cards: will they pass or fail in the fight against pediatric obesity?. Curr Opin Pediatr 2009; 21: 431-436
• 21 Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 22 Neumark-Sztainer D, Bauer KW, Friend S et al. Family weight talk and dieting: how much do they matter for body dissatisfaction and disordered eating behaviors in adolescent girls?. J Adolesc Health 2010; 47: 270-276
• 23 Yeckel CW, Taksali SE, Dziura J et al. The normal glucose tolerance continuum in obese youth: evidence for impairment in beta-cell function independent of insulin resistance. J Clin Endocrinol Metab 2005; 90: 747-754
• 24 Taksali SE, Caprio S, Dziura J et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 2008; 57: 367-371
• 25 Tan CY, Vidal-Puig A. Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans 2008; 36: 935-940
• 26 Nafiu OO, Burke C, Lee J et al. Neck circumference as a screening measure for identifying children with high body mass index. Pediatrics 2010; 126: 306-310
• 27 Kurtoglu S, Hatipoglu N, Mazicioglu MM et al. Neck circumference as a novel parameter to determine metabolic risk factors in obese children. Eur J Clin Invest 2011; 42: 623-630
• 28 Mangge H, Almer G, Haj-Yahya S et al. Nuchal thickness of subcutaneous adipose tissue is tightly associated with an increased LMW/total adiponectin ratio in obese juveniles. Atherosclerosis 2009; 203: 277-283
• 29 Weiss R, Dufour S, Taksali SE et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin restistance, and altered myocellular and abdominal fat partitioning. Lancet 2003; 362: 951-957
• 30 Klöting N, Fasshauer M, Dietrich A et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010; 299: 506-515
• 31 Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176
• 32 Stefan N, Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616
• 33 Nobili V, Parola M, Alisi A et al. Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. Int J Mol Med 2010; 26: 471-476
• 34 Tsouli SG, Liberopoulos EN, Mikhailidis DP et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. Metabolism 2006; 55: 1293-1301
• 35 Hongo M, Hidaka H, Sakaguchi S et al. Association between serum uric acid levels and cardiometabolic risk factors among Japanese junior high school students. Circ J 2010; 74: 1570-1577
• 36 Baker JF, Krishnan E, Chen L et al. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. Am J Med 2005; 118: 816-826
• 37 Cirillo P, Sato W, Reungjui S et al. Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol 2006; 17: 165-168
• 38 Sangun Ö, Dündar B, Köşker M et al. Prevalence of metabolic syndrome in obese children and adolescents using three different criteria and evaluation of risk factors. J Clin Res Pediatr Endocrinol 2011; 3: 70-76
• 39 Kantartzis K, Machann J, Schick F et al. Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia 2011; 54: 864-868
• 40 Stefan N, Kantartzis K, Machann J et al. Global trends in body-mass index. Lancet 2011; 377: 1917